Evidence map›Paper›PMID 35293277›Full record

ArticlemAbs

CLEC5a-directed bispecific antibody for effective cellular phagocytosis.

Vivekananda Kedage, Diego Ellerman, Mingjian Fei, Wei-Ching Liang, Gu Zhang, Eric Cheng, Juan Zhang, Yongmei Chen, Haochu Huang, Wyne P Lee and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Vivekananda KedageDepartment of Molecular Oncology, Genentech, South San Francisco, California, USA.
Diego EllermanDepartment of Protein Chemistry and Structural Biology, Genentech, South San Francisco, California, USA.ORCID 0000-0002-3056-3600
Mingjian FeiDepartment of Molecular Oncology, Genentech, South San Francisco, California, USA.
Wei-Ching LiangDepartment of Antibody Engineering, Genentech, South San Francisco, California, USA.
Gu ZhangDepartment of Molecular Oncology, Genentech, South San Francisco, California, USA.
Eric ChengDepartment of Immunology, Genentech, South San Francisco, California, USA.
Juan ZhangDepartment of Immunology, Genentech, South San Francisco, California, USA.
Yongmei ChenDepartment of Antibody Engineering, Genentech, South San Francisco, California, USA.
Haochu HuangDepartment of Molecular Oncology, Genentech, South San Francisco, California, USA.
Wyne P LeeDepartment of Immunology, Genentech, South San Francisco, California, USA.
Yan WuDepartment of Antibody Engineering, Genentech, South San Francisco, California, USA.
Minhong YanDepartment of Molecular Oncology, Genentech, South San Francisco, California, USA.ORCID 0000-0001-6126-9714
Molecular Oncology (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB). Here, we describe a bispecific antibody approach that harnesses phagocytic receptor CLEC5A (C-type Lectin Domain Containing 5A) to drive Fcγ receptor-independent phagocytosis, potentially circumventing the negative impact of FcγRIIB. First, we established the effectiveness of such an approach by constructing bispecific antibodies that simultaneously target CLEC5A and live B cells. Furthermore, we demonstrated its in vivo application for regulatory T cell depletion and subsequent tumor regression.

Indexed as

Antibodies, BispecificB-LymphocytesPhagocytosisReceptors, IgGT-Lymphocytes, RegulatoryAntibodies, BispecificReceptors, IgGbispecific antibodyCLEC5AFcγ receptorPhagocytosistregtumor-associated macrophage

Identifiers

PMID35293277
PMCPMC8932924
OpenAlexW4221076730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.